AMD Projects: Deadly Disease Databases

Total Page：16

File Type：pdf, Size：1020Kb

CDC’s AMD Program AMD Projects Innovate • Transform • Protect CDC’s Advanced Molecular Detection (AMD) program fosters scientific innovation in genomic sequencing, epidemiology, and bioinformatics to transform public health and protect people from disease threats. AMD Project: Deadly Disease Databases Whole genome analysis and database development for anthrax (Bacillus anthracis), melioidosis (Burkholderia pseudomallei), and Brucellosis (Brucella spp.) Epidemiologists and forensic professionals can use whole genome sequencing – a way of determining an organism’s complete, detailed genome – and large databases to determine the source of dangerous germs. Having a large, accessible collection of disease pathogens could help scientists quickly find out if a certain illness is naturally occurring or the result of bioterrorism. CDC is establishing a public database where scientists from around the world can share information about these potentially deadly CDC is establishing public databases so that diseases. CDC scientists have begun sequencing the organisms that scientists from around the world can share information about deadly diseases like cause anthrax (Bacillus anthracis), brucellosis (Brucella spp.), and anthrax, brucellosis, and melioidosis. melioidosis (Burkholderia pseudomallei), three pathogens that could occur naturally or as the result of bioterrorism. Current methods of determining the genetic structure of these organisms are not standardized and sometimes not effective. Using whole genome sequencing for these pathogens will allow scientists www.cdc.gov/amd Updated: May 2017 to accurately and quickly find the geographic origin of the isolates and will improve overall knowledge and understanding of them. Having a detailed database of these genomes will also ensure quicker and more effective responses to outbreaks. For more information on anthrax, please visit www.cdc.gov/anthrax/index.html. For more information on brucellosis, please visit www.cdc.gov/brucellosis/index.html. For more information on melioidiosis, please visit www.cdc.gov/melioidosis/index.html. 2017 Project Completion This project reached a successful conclusion in 2017 with the launch of the Microbial Gene Atlas, or MiGA. Developed in partnership with Georgia Institute of Technology. MiGA allows scientists around the world to view, share, and compare deadly strains of bacteria, such as anthrax, so we can more rapidly determine whether a disease outbreak is the result of a natural occurrence or linked to bioterrorism. MiGA gives scientists the ability to analyze hundreds of genomes of a bacterial species in just a few hours. Genetically tracing bacterial strain back to the source of someone’s infection will help investigators rapidly identify where an outbreak started and take measures to stop it. Updated: May 2017 .

Copy Link

Recommended publications

Reportable Diseases and Conditions
KINGS COUNTY DEPARTMENT of PUBLIC HEALTH 330 CAMPUS DRIVE, HANFORD, CA 93230 REPORTABLE DISEASES AND CONDITIONS Title 17, California Code of Regulations, §2500, requires that known or suspected cases of any of the diseases or conditions listed below are to be reported to the local health jurisdiction within the specified time frame: REPORT IMMEDIATELY BY PHONE During Business Hours: (559) 852-2579 After Hours: (559) 852-2720 for Immediate Reportable Disease and Conditions Anthrax Escherichia coli: Shiga Toxin producing (STEC), Rabies (Specify Human or Animal) Botulism (Specify Infant, Foodborne, Wound, Other) including E. coli O157:H7 Scrombroid Fish Poisoning Brucellosis, Human Flavivirus Infection of Undetermined Species Shiga Toxin (Detected in Feces) Cholera Foodborne Disease (2 or More Cases) Smallpox (Variola) Ciguatera Fish Poisoning Hemolytic Uremic Syndrome Tularemia, human Dengue Virus Infection Influenza, Novel Strains, Human Viral Hemorrhagic Fever (Crimean-Congo, Ebola, Diphtheria Measles (Rubeola) Lassa, and Marburg Viruses) Domonic Acid Poisoning (Amnesic Shellfish Meningococcal Infections Yellow Fever Poisoning) Novel Virus Infection with Pandemic Potential Zika Virus Infection Paralytic Shellfish Poisoning Plague (Specify Human or Animal) Immediately report the occurrence of any unusual disease OR outbreaks of any disease. REPORT BY PHONE, FAX, MAIL WITHIN ONE (1) WORKING DAY Phone: (559) 852-2579 Fax: (559) 589-0482 Mail: 330 Campus Drive, Hanford 93230 Conditions may also be reported electronically via the California
[Show full text]
2012 Case Definitions Infectious Disease
Arizona Department of Health Services Case Definitions for Reportable Communicable Morbidities 2012 TABLE OF CONTENTS Definition of Terms Used in Case Classification .......................................................................................................... 6 Definition of Bi-national Case ............................................................................................................................................. 7 ------------------------------------------------------------------------------------------------------- ............................................... 7 AMEBIASIS ............................................................................................................................................................................. 8 ANTHRAX (β) ......................................................................................................................................................................... 9 ASEPTIC MENINGITIS (viral) ......................................................................................................................................... 11 BASIDIOBOLOMYCOSIS ................................................................................................................................................. 12 BOTULISM, FOODBORNE (β) ....................................................................................................................................... 13 BOTULISM, INFANT (β) ...................................................................................................................................................
[Show full text]
LIST of REPORTABLE COMMUNICABLE DISEASES in BC July 2009
LIST OF REPORTABLE COMMUNICABLE DISEASES IN BC July 2009 Schedule A: Reportable by all sources, including Laboratories Meningococcal Disease, All Invasive including “Primary Meningococcal Acquired Immune Deficiency Syndrome Pneumonia” and “Primary Meningococcal Anthrax Conjunctivitis” Botulism Mumps Brucellosis Neonatal Group B Streptococcal Infection Chancroid Paralytic Shellfish Poisoning (PSP) Cholera Pertussis (Whooping Cough) Congenital Infections: Plague Toxoplasmosis Poliomyelitis Rubella Rabies Cytomegalovirus Reye Syndrome Herpes Simplex Rubella Varicella-Zoster Severe Acute Respiratory Syndrome (SARS) Hepatitis B Virus Smallpox Listeriosis and any other congenital infection Streptococcus pneumoniae Infection, Invasive Creutzfeldt-Jacob Disease Syphilis Cryptococcal infection Tetanus Cryptosporidiosis Transfusion Transmitted Infection Cyclospora infection Tuberculosis Diffuse Lamellar Keratitis Tularemia Diphtheria: Typhoid Fever and Paratyphoid Fever Cases Waterborne Illness Carriers All causes Encephalitis: West Nile Virus Infection Post-infectious Yellow Fever Subacute sclerosing panencephalitis Vaccine-related Viral Schedule B: Reportable by Laboratories only Foodborne illness: All causes All specific bacterial and viral stool pathogens: Gastroenteritis epidemic: (i) Bacterial: Bacterial Campylobacter Parasitic Salmonella Viral Shigella Genital Chlamydia Infection Yersinia Giardiasis (ii) Viral Gonorrhea – all sites Amoebiasis Group A Streptococcal Disease, Invasive Borrelia burgdorferi infection H5 and H7 strains of the
[Show full text]
Veterinary Services Newsletter August 2017
August 2017 Veterinary Services Newsletter August 2017 Wildlife Health Laboratory Veterinary Services Staff NALHN Certification: The Wildlife Health Laboratory has been working towards joining the National Animal Health Laboratory Network (NALHN) in order to have ac- cess to all CWD testing kits. The commercial test kits for CWD are now restricted, and Branch Supervisor/Wildlife only NALHN approved laboratories have access to all the kits that are currently availa- Veterinarian: Dr. Mary ble. To be considered for the program, our laboratory must meet the ISO 17025 stand- Wood ards of quality control that assure our laboratory is consistently and reliably producing Laboratory Supervisor: accurate results. In addition, our laboratory will be regularly inspected by APHIS Veter- Hank Edwards inary Services, and we will be required to complete annual competency tests. Although we have been meeting most of the ISO standards for several years, applying to the Senior Lab Scientist: NAHLN has encouraged us to tighten many of our procedures and quality control moni- Hally Killion toring. We hope to have the application submitted by the middle of August and we have our first APHIS inspection in September. Senior Lab Scientist: Jessica Jennings-Gaines Brucellosis Lab Assistant: New CWD area for elk: The Wildlife Health Laboratory confirmed the first case of Kylie Sinclair CWD in an elk from hunt area 48. This animal was captured in elk hunt area 33 as part of the elk movement study in the Bighorns to study Brucellosis. She was found dead in Wildlife Disease Specialist: hunt area 48, near the very southeastern corner of Washakie County.
[Show full text]
Insights Into the Pathogenicity of Burkholderia Pseudomallei
REVIEWS Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei W. Joost Wiersinga*, Tom van der Poll*, Nicholas J. White‡§, Nicholas P. Day‡§ and Sharon J. Peacock‡§ Abstract | Burkholderia pseudomallei is a potential bioterror agent and the causative agent of melioidosis, a severe disease that is endemic in areas of Southeast Asia and Northern Australia. Infection is often associated with bacterial dissemination to distant sites, and there are many possible disease manifestations, with melioidosis septic shock being the most severe. Eradication of the organism following infection is difficult, with a slow fever-clearance time, the need for prolonged antibiotic therapy and a high rate of relapse if therapy is not completed. Mortality from melioidosis septic shock remains high despite appropriate antimicrobial therapy. Prevention of disease and a reduction in mortality and the rate of relapse are priority areas for future research efforts. Studying how the disease is acquired and the host–pathogen interactions involved will underpin these efforts; this review presents an overview of current knowledge in these areas, highlighting key topics for evaluation. Melioidosis is a serious disease caused by the aerobic, rifamycins, colistin and aminoglycosides), but is usually Gram-negative soil-dwelling bacillus Burkholderia pseu- susceptible to amoxicillin-clavulanate, chloramphenicol, domallei and is most common in Southeast Asia and doxycycline, trimethoprim-sulphamethoxazole, ureido- Northern Australia. Melioidosis is responsible for 20% of penicillins, ceftazidime and carbapenems2,4. Treatment all community-acquired septicaemias and 40% of sepsis- is required for 20 weeks and is divided into intravenous related mortality in northeast Thailand. Reported cases are and oral phases2,4. Initial intravenous therapy is given likely to represent ‘the tip of the iceberg’1,2, as confirmation for 10–14 days; ceftazidime or a carbapenem are the of disease depends on bacterial isolation, a technique that drugs of choice.
[Show full text]
Antigen Detection Assay for the Diagnosis of Melioidosis
PI: Title: Antigen Detection assay for the Diagnosis of Melioidosis Received: 12/05/2013 FOA: PA10-124 Council: 05/2014 Competition ID: ADOBE-FORMS-B1 FOA Title: NIAID ADVANCED TECHNOLOGY STTR (NIAID-AT-STTR [R41/R42]) 2 R42 AI102482-03 Dual: Accession Number: 3650491 IPF: 3966401 Organization: INBIOS INTERNATIONAL, INC. Former Number: Department: IRG/SRG: ZRG1 IDM-V (12)B AIDS: N Expedited: N Subtotal Direct Costs Animals: N New Investigator: N (excludes consortium F&A) Humans: Y Early Stage Investigator: N Year 3: Clinical Trial: N Year 4: Current HS Code: E4 Year 5: HESC: N Senior/Key Personnel: Organization: Role Category: Always follow your funding opportunity's instructions for application format. Although this application demonstrates good grantsmanship, time has passed since the grantee applied. The sample may not reflect the latest format or rules. NIAID posts new samples periodically: https://www.niaid.nih.gov/grants-contracts/sample-applications The text of the application is copyrighted. You may use it only for nonprofit educational purposes provided the document remains unchanged and the PI, the grantee organization, and NIAID are credited. Note on Section 508 conformance and accessibility: We have reformatted these samples to improve accessibility for people with disabilities and users of assistive technology. If you have trouble accessing the content, please contact the NIAID Office of Knowledge and Educational Resources at [email protected]. Additions for Review Accepted Publication Accepted manuscript news Post-submission supplemental material. Information about manuscript accepted for publication. OMB Number: 4040-0001 Expiration Date: 06/30/2011 APPLICATION FOR FEDERAL ASSISTANCE 3. DATE RECEIVED BY STATE State Application Identifier SF 424 (R&R) 1.
[Show full text]
Disease Control Newsletter Is Available on the MDH IDCN Web Site: (
ISEASE ONTROL EWSLETTER DVolume 46, Number 1 (pages 1-30) C N 2019 Annual Summary of Communicable Diseases Reported to the Minnesota Department of Health, 2018 Introduction Anaplasmosis Assessment of the population’s health is a core public health function. Anaplasmosis, caused by Anaplasma Surveillance for communicable diseases is one type of assessment. Epidemiologic phagocytophilum, is transmitted surveillance is the systematic collection, analysis, and dissemination of health by bites from Ixodes scapularis, data for the planning, implementation, and evaluation of health programs. the blacklegged tick. Although the The Minnesota Department of Health (MDH) collects information on infectious organism that causes anaplasmosis diseases for the purposes of determining disease impact, assessing trends in was previously known by other disease occurrence, characterizing affected populations, prioritizing control names and thought to be a part of efforts, and evaluating prevention strategies. Prompt reporting allows outbreaks the genus Ehrlichia, anaplasmosis and to be recognized in a timely fashion when control measures are most likely to be ehrlichiosis (due to E. chaffeensis) are effective in preventing additional cases. distinct diseases caused by different rickettsial species. The same tick vector In Minnesota, communicable disease reporting is centralized, whereby reporting also transmits the etiologic agents of sources submit standardized reports to MDH. Cases of disease are reported Lyme disease, babesiosis, ehrlichiosis pursuant to Minnesota Rules Governing Communicable Diseases (Minnesota (due to E. muris), and Powassan Rules 4605.7000 -4605.7800). The diseases listed in Table 1 must be reported virus. In rare circumstances, A. to MDH. As stated in the rules, physicians, health care facilities, laboratories, phagocytophilum may be transmitted veterinarians, and others are required to report these diseases.
[Show full text]
Monthly Reportable Diseases Summary
Monthly Reportable Diseases Summary June 2021 The data in the Monthly Disease Reports are provisional, based on current reports in the Michigan Disease Surveillance System (MDSS) made by local public health departments. The MDSS is a dynamic, continually active system; counts of disease are constantly changing as cases are investigated, confirmed as cases, or ruled out as not meeting the case definition. Each Monthly Disease Report reflects this constant activity as the numbers may slightly fluctuate each month. Therefore, it should be kept in mind that numbers in the Monthly Disease Reports are NOT final and should be used only to generally monitor Ottawa County trends over time. Unknown, suspect, probable and confirmed cases of the reportable condition are included in the report. An updated report is published each month. Specific data requests and questions should be directed to the following: Compiled by Derick N. Chia, MPH Epidemiologist [email protected] We value your feedback. Please use this QR code or click on the link below to tell us what you think of this report: Link to Survey 12251 James Street Holland, MI 49424-9661 www.miottawa.org/healthdata June 2021 Reportable conditions that are italicized have an accompanying graph at the end of the monthly section. Cases Reported in Last 4 Months** Year Total Through June Year End Disease Group Reportable Condition Mar-21 Apr-21 May-21 Jun-21 2018 2019 2020 2021 2020 Foodborne Amebiasis - 1 - - - - - 1 - Botulism - Foodborne - - - - - - - - - Campylobacter 2 4 1 6 33 29 16 22
[Show full text]
Scientific Consultation Summary
GLOBAL ANTIBIOTIC RESEARCH AND DEVELOPMENT (GARD) PARTNERSHIP Developing new antibiotic treatments, promoting responsible SCIENTIFIC use, and ensuring access for all A joint WHO/DNDi initiative incubated by DNDi in CONSULTATION support of the Global Action Plan for Antimicrobial Resistance SUMMARY Institut Pasteur, France / 29 February 2016 Background Following recommendations made during the technical consultation meeting in November 2015 at the World Health Organization, GARD rapidly undertook an informal process of scoping for potential initial project proposals. A set of general selection criteria was established and a basic template was circulated to GARD’s scientific contacts and networks. This was not a broad call for proposals as GARD is currently at the very early stages of incubation and would require greater resources in order to manage such a process. The template is now online. This process, which began late December 2015 and is still ongoing, rendered 10 project proposals that were discussed during the meeting after briefings with each of the project proposers as the projects were being developed. The aim of this initial scientific consultation was to help GARD evolve from the initial scientific strategy articulated in the initial and revised GARD concept notes, determine priority areas and short- to medium-term projects to be launched within one year. Longer-term (upstream) projects will also be considered as GARD builds its R&D pipeline. Summary of discussions The following aims to provide a summary of the discussions of the 29 February meeting. Introductory presentations were made in order to provide a common context in which the projects were to be discussed, including the respective roles of DNDi and WHO in GARD, the work of WHO, the emphasis on embedding conservation and access in each project from the outset, and the need to consider diagnostics in the R&D equation.
[Show full text]
KDHE's Notifiable Disease List
REPORTABLE DISEASES IN KANSAS (K.S.A. 65-118, 65-128, 65-6001 - 65-6007, K.A.R. 28-1-2, 28-1-4, and 28-1-18. Changes effective as of 5/11/2018) For 4-hour reportable diseases report to the KDHE Epidemiology Hotline: 877-427-7317. For all other reportable diseases fax a Kansas Reportable Disease Form and any lab results to your local health department or to KDHE: 877-427-7318 within 24 hours or by the next business day. Acute flaccid myelitis Influenza, novel A virus infection Anthrax Legionellosis Anaplasmosis Listeriosis Arboviral disease, neuroinvasive and nonneuroinvasive Lyme disease (including chikungunya virus, dengue virus, La Malaria Crosse, West Nile virus, and Zika virus) Measles (rubeola) Babesiosis Meningococcal disease Blood lead levels (any results) Mumps Botulism Pertussis (whooping cough) Brucellosis Plague (Yersinia pestis) Campylobacteriosis Poliovirus Candida auris Psittacosis Carbapenem-resistant bacterial infection or Q Fever (Coxiella burnetii, acute and chronic) colonization Rabies, human Carbon monoxide poisoning Rabies, animal Chancroid Rubella Chickenpox (varicella) Salmonellosis, including typhoid fever Chlamydia trachomatis infection Severe Acute Respiratory Syndrome-associated Cholera coronavirus (SARS-CoV) Coccidioidomycosis Shiga toxin-producing Escherichia coli (STEC) Cryptosporidiosis Shigellosis Cyclosporiasis Smallpox Diphtheria Spotted fever rickettsiosis Ehrlichiosis Streptococcus pneumoniae, invasive disease Giardiasis Syphilis, all stages, including congenital syphilis Gonorrhea
[Show full text]
Melioidosis Fact Sheet
Melioidosis Fact Sheet What is melioidosis? Melioidosis, also known as Whitmore’s disease, is an uncommon bacterial infection caused by Burkholderia pseudomallei. The disease affects humans and animals. Individuals acquire the bacteria through direct contact with contaminated soil and surface waters. Who gets melioidosis? Melioidosis is a rare disease in the United States, but it is more common in tropical or subtropical areas of the world, including Southeast Asia and Australia. People who get melioidosis include agricultural workers, military personnel, travelers to areas where the disease is common, construction workers, and people who have contact with contaminated soil or water. Individuals with underlying diseases, such as diabetes mellitus, kidney or liver disease, chronic lung disease, thalassemia (a form of anemia), cancer or another immune-compromising condition, are at higher risk for developing the infection. How is melioidosis spread? The bacteria that cause melioidosis usually enter the body through inhalation of soil dust or water droplets, contact with contaminated soil through breaks in the skin, or by ingestion of contaminated water. Person-to-person transmission is very rare, but can occur through contact with blood or body fluids of an infected person. Laboratory-acquired infections are also rare, but can occur, especially if procedures produce aerosols. What are the symptoms of melioidosis? The bacteria can infect the skin or lungs or can spread throughout the body. The symptoms that a person might develop depend on the location of infection. Some people might not develop any symptoms. Localized infections, such as skin wounds, are characterized by pain or swelling at a particular site, fever, ulceration, or abscess.
[Show full text]
Development of Diagnostic Assays for Melioidosis, Tularemia, Plague And
University of Nevada, Reno Development of Diagnostic Assays for Melioidosis, Tularemia, Plague and COVID19 A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Cellular and Molecular Biology By Derrick Hau Dr. David P. AuCoin / Dissertation Advisor December 2020 THE GRADUATE• SCHOOL We recommend that the dissertation prepared under our supervision by entitled be accepted in partial fulfillment of the requirements for the degree of Advisor Committee Member Committee Member Committee Member Graduate School Representative David W. Zeh, Ph.D., Dean Graduate School December 2020 i Abstract Infectious diseases are caused by pathogenic organisms which can be spread throughout communities by direct and indirect contact. Burkholderia pseudomallei, Francisella tularenisis, and Yersinia pestis are the causative agents of melioidosis, tularemia and plague, respectively. These bacteria pertain to the United States of America Federal Select Agent Program as they are associated with high mortality rates, lack of medical interventions and are potential agents of bioterrorism. The novel coronavirus disease (COVID-19) has resulted in a global pandemic due to the highly infectious nature and elevated virulence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Proper diagnosis of these infections is warranted to administer appropriate medical care and minimize further spreading. Current practices of diagnosing melioidosis, tularemia, plague and COVID-19 are inadequate due to limited resources and the untimely nature of the techniques. Commonly, diagnosing an infectious disease is by the direct detection of the causative agent. Isolation by bacterial culture is the gold standard for melioidosis, tularemia and plague infections; detection of SAR-CoV-2 nucleic acid by real-time polymerase chain reaction (RT-PCR) is the gold standard for diagnosing COVID-19.
[Show full text]